PLX

2.9005.23%
ER

Eliot Richard Forster

Independent Chairman

Dr. Eliot Richard Forster, Ph.D, MBA, serves as Advisor to the Board at CellmAbs and was its Non-Executive Director. He is Chief Executive Officer of Levicept Ltd. from November 2023. He serves as Chairman of the Board at Granite Bio AG since December 2024. He serves on the Boards of Tessellate BIO since September 2023 and Ochre Bio since May 2023. He serves as Independent Chairman of Protalix BioTherapeutics, Inc. since September 14, 2023. He served as CEO and President at F-star Therapeutics, Inc. since, November 20, 2020 and serves as its Director. He served as Non-Executive Chairman of Avacta Group plc since June 11, 2018 until June 2024. He has been Independent Non-Executive Director of Immatics N.V. since July 1, 2021. Dr. Forster served as Interim Supervisory Director at Immatics N.V. since September 14, 2020 until June 17, 2021 and served as its Supervisory Director since June 17, 2021 until July 1, 2021. Before joining F-star in 2018, he served as Chief Executive Officer of Immunocure Limited since 2015 until February 2018. He successfully steered the company’s strategy in immuno-oncology (IO), raising for Series A and establishing clinical collaborations with global pharmaceutical companies including AstraZeneca, GSK and Roche. He served as the Chief Executive Officer of f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. since October 15, 2018 and served as its President since October 2020. Dr. Forster served as the Chief Executive Officer of Creabilis Therapeutics S.r.l. since September 2010. Dr. Forster has been Non-Executive Chairman of ADC Therapeutics SAsince June 11, 2018. He held senior leadership positions at Pfizer (including Head of EU Development & Operations) and GSK. During his pharma tenure, he played a critical role in the clinical development of Celebrex® (celecoxib) and Relpax® (eletriptan). Dr. Forster served at Solace Pharmaceuticals Inc. until May 2010. He served as the Chief Executive Officer of Solace Pharmaceuticals Inc. since May 14, 2007. Dr. Forster served as the Chief Executive Officer at Solace Pharmaceuticals (UK) Ltd. He served as the Chief Executive Officer of Creabilis SA. Dr. Forster focuses on treating the causes of both chronic neuropathic and inflammatory pain. He was head of European Union development and development operations in the European Union and Asia at Pfizer. During his tenure at Pfizer, Dr. Forster was involved in the development of a number of pain drugs, including also Relpax (TM), Celebrex (TM) and Bextra (TM). He oversaw drug development activities across Europe and established Pfizer's development activities in Asia as a Senior Executive. He was Clinical Research Manager at GlaxoSmithKline. Previously, Dr. Forster was in Pfizer's Global Research and Development group where he served a variety of senior roles. Dr. Forster spent in clinical research in Wellcome. Dr. Forster had been a Director of Solace Pharmaceuticals, Inc. since May 14, 2007. He serves as a Founding Member and Non-Executive Director of South East Health Technologies Alliance Ltd. (SEHTA). He is founding Chairman of the MedCity project. He serves as Director of MedCity Ltd, GERM Limited, Advanced Oxford CIC, Biobreak UK Limited and GMEC Management Company Limited. He serves as Member of Scientific Advisory Panel at Oxford Capital Partners LLP. Dr. Forster is an Advisor to the UKTI Life Sciences Strategy Board. Dr. Forster served as a Director of Creabilis SA, Immunocore Nominees Limited, Creabilis Holdings Limited, Creabilis UK Limited, Immunocore Limited and Poet in the City Trading Limited. He served as Member of Advisory Board at Grey Wolf Therapeutics until August 2024. He served as a Non-Executive Director of Oxford BioTherapeutics Limited. He served as a Director of Spinifex Pharmaceuticals Pty Ltd. He served as an Observer at Spinifex Pharmaceuticals Pty Ltd. He served as a Non-Executive Director of Atlantic Healthcare plc. He is an honorary visiting Professor of Molecular and Clinical Cancer Medicine at the University of Liverpool and an honorary international visiting Professor at the University of Pavia. He is also Board member of OSCHR (Office for Strategic Coordination of Health Research) and the National Genomics Board. Dr. Forster holds a Ph.D. in Neurophysiology between 1988 & 1992 and a B.Sc. (Hons) in physiology from the University of Liverpool and an M.B.A. from Henley Management College between 1999 & 2001.

Positions